Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?

The role of the ACE2 enzyme in the COVID-19 infection is 2-fold, with opposing implications for the disease development. 1. The membrane bound angiotensin converting enzyme 2 (ACE2) serves as the entry point of COVID-19 2. Conversely, it supports an anti-inflammatory pathway. This led to the controv...

Full description

Bibliographic Details
Main Author: Harald Murck
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01239/full
id doaj-3c12116ccece46d99dc20d93f691e307
record_format Article
spelling doaj-3c12116ccece46d99dc20d93f691e3072020-11-25T03:17:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-05-011110.3389/fimmu.2020.01239549292Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?Harald Murck0Harald Murck1Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, GermanyMurck-Neuroscience LLC, Westfield, NJ, United StatesThe role of the ACE2 enzyme in the COVID-19 infection is 2-fold, with opposing implications for the disease development. 1. The membrane bound angiotensin converting enzyme 2 (ACE2) serves as the entry point of COVID-19 2. Conversely, it supports an anti-inflammatory pathway. This led to the controversy of the impact of medications, which influence its expression. ACE2 is part of the wider renin-angiotensin-aldosterone system (RAAS) and is upregulated via compounds, which inhibits the classical ACE, thereby plasma aldosterone and aldosterone receptor (MR) activation. MR activation may therefore protect organs from binding the COVID-19 by reducing ACE2 expression. Glycyrrhizin (GL) is a frequent component in traditional Chinese medicines, which have been used to control COVID-19 infections. Its systemically active metabolite glycyrrhetinic acid (GA) inhibits 11beta hydroxysteroid dehydrogenase(11betaHSD2) and activates MR in organs, which express this enzyme, including the lungs. Does this affect the protective effect of ACE2? Importantly, GL has anti-inflammatory properties by itself via toll like receptor 4 (TLR4) antagonism and therefore compensates for the reduced protection of the downregulated ACE2. Finally, a direct effect of GL or GA to reduce virus transmission exists, which may involve reduced expression of type 2 transmembrane serine protease (TMPRSS2), which is required for virus uptake. Glycyrrhizin may reduce the severity of an infection with COVID-19 at the two stages of the COVID-19 induced disease process, 1. To block the number of entry points and 2. provide an ACE2 independent anti-inflammatory mechanism.https://www.frontiersin.org/article/10.3389/fimmu.2020.01239/fullCorona virusCOVID-19glycyrrhizinmineralocorticoid receptorinflammationtoll like receptor 4 (TLR4)
collection DOAJ
language English
format Article
sources DOAJ
author Harald Murck
Harald Murck
spellingShingle Harald Murck
Harald Murck
Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
Frontiers in Immunology
Corona virus
COVID-19
glycyrrhizin
mineralocorticoid receptor
inflammation
toll like receptor 4 (TLR4)
author_facet Harald Murck
Harald Murck
author_sort Harald Murck
title Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
title_short Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
title_full Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
title_fullStr Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
title_full_unstemmed Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
title_sort symptomatic protective action of glycyrrhizin (licorice) in covid-19 infection?
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2020-05-01
description The role of the ACE2 enzyme in the COVID-19 infection is 2-fold, with opposing implications for the disease development. 1. The membrane bound angiotensin converting enzyme 2 (ACE2) serves as the entry point of COVID-19 2. Conversely, it supports an anti-inflammatory pathway. This led to the controversy of the impact of medications, which influence its expression. ACE2 is part of the wider renin-angiotensin-aldosterone system (RAAS) and is upregulated via compounds, which inhibits the classical ACE, thereby plasma aldosterone and aldosterone receptor (MR) activation. MR activation may therefore protect organs from binding the COVID-19 by reducing ACE2 expression. Glycyrrhizin (GL) is a frequent component in traditional Chinese medicines, which have been used to control COVID-19 infections. Its systemically active metabolite glycyrrhetinic acid (GA) inhibits 11beta hydroxysteroid dehydrogenase(11betaHSD2) and activates MR in organs, which express this enzyme, including the lungs. Does this affect the protective effect of ACE2? Importantly, GL has anti-inflammatory properties by itself via toll like receptor 4 (TLR4) antagonism and therefore compensates for the reduced protection of the downregulated ACE2. Finally, a direct effect of GL or GA to reduce virus transmission exists, which may involve reduced expression of type 2 transmembrane serine protease (TMPRSS2), which is required for virus uptake. Glycyrrhizin may reduce the severity of an infection with COVID-19 at the two stages of the COVID-19 induced disease process, 1. To block the number of entry points and 2. provide an ACE2 independent anti-inflammatory mechanism.
topic Corona virus
COVID-19
glycyrrhizin
mineralocorticoid receptor
inflammation
toll like receptor 4 (TLR4)
url https://www.frontiersin.org/article/10.3389/fimmu.2020.01239/full
work_keys_str_mv AT haraldmurck symptomaticprotectiveactionofglycyrrhizinlicoriceincovid19infection
AT haraldmurck symptomaticprotectiveactionofglycyrrhizinlicoriceincovid19infection
_version_ 1724631913696591872